Share on LinkedInShare on LinkedIn

ARTICLE · 30 MARCH 2021

Should The Patent Procurement Process Fall Under The Remit Of Antitrust Law? – A US Perspective

Bristows LLP
Bristows LLP
Contributor
Bristows LLP

Bristows LLP

We are Bristows, the world’s leading specialist law firm for clients that innovate. We are a London...

View firm profile
Explore more from Bristows LLP

Following on from a recent CLIP of the month post on the lawfulness of strategic patenting under EU competition law, an amicus curiae brief recently filed by the US Department of Justice provides an insight into the US position ...

United StatesAntitrust/Competition Law

Following on from a recent CLIP of the month post on the lawfulness of strategic patenting under EU competition law, an amicus curiae brief recently filed by the US Department of Justice ("DoJ") provides an insight into the US position on this grey area of antitrust law. The brief was submitted in a suit against Abbvie concerning its patenting strategy relating to its monoclonal antibody Humira. This case has been followed closely by competition lawyers and biotech companies as it is the first of its kind to scrutinise potential antitrust issues relating to biologics (see our previous article here).

Background to the case

In March 2019, an antitrust suit was filed against AbbVie and biosimilar companies in the District Court (Northern District of Illinois) on behalf of indirect US purchasers of Humira (adalimumab). The plaintiffs claimed, inter alia, that Abbvie's filing of over 100 patents for Humira amounted to a patent thicket, designed to maintain its

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from